Mod­er­na, Mer­ck say their can­cer vac­cine re­duces metas­tases by 65% in PhII study of high-risk melanoma: #AS­CO23

CHICA­GO — Mod­er­na’s am­bi­tions to chart a fu­ture be­yond Covid-19 shots and un­leash its mR­NA tech­nolo­gies on can­cer just got a lot brighter.

The mR­NA pi­o­neer and Mer­ck an­nounced new da­ta on Mon­day at AS­CO’s an­nu­al meet­ing for their per­son­al­ized can­cer vac­cine — made from mR­NA-en­cod­ing mol­e­c­u­lar mugshots unique to an in­di­vid­ual’s tu­mor. In pa­tients who un­der­went surgery to re­move high-risk skin can­cer, a com­bi­na­tion of the cus­tom shot and Mer­ck’s im­munother­a­py Keytru­da sig­nif­i­cant­ly re­duced the risk of de­vel­op­ing dead­ly metas­tases by 65% com­pared to pa­tients tak­ing Keytru­da alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER